- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01732185
Genetic and Molecular Abnormalities in Congenital Cystic Adenomatoid Malformations (MAKP)
September 1, 2025 updated by: Assistance Publique - Hôpitaux de Paris
The aim of this study is to identify genetic abnormalities and molecular pathways associated with the occurrence of CCAM.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Congenital lung malformations are rare diseases, characterized by the coexistence in the same individual of normal lung and localized lung malformation.
Among these malformations, congenital cystic adenomatoid malformations (CCAM) represent the most important group, with an estimated incidence between 1/11 000 and 1/35 000 births.
The precise mechanisms leading to these lung malformations remain poorly understood.
This project aims to identify key genetic and/or molecular mechanisms associated with the occurrence of CCAM.
CCAMs are collected during postnatal surgical resection.
Parental agreement is required.
A standardised histologic description of malformations is performed for each sample.
Normal lung tissue at the periphery of the malformation is considered as control.
Malformations will be analyzed in a systematic way by proteome and transcriptome, after laser microdissection.
Somatic genetic abnormalities will also systematically be sought.
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris, France, 75015
- Necker-Enfants Malades Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 8 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Children < 8 years
- Thoracic surgery for congenital lung malformation
- Parental written consent
Exclusion Criteria:
- Children > 8 years
- Previous infection of the malformation
- Parental rebutal
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Patient
congenital cystic adenomatoid malformations
|
Blood and histological samples will be done at day of the inclusion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
mRNA expression
Time Frame: at Day 0
|
Transcriptomic analysis
|
at Day 0
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Protein expression
Time Frame: at Day 0
|
Proteomic expression
|
at Day 0
|
|
Somatic genetic abnormalities
Time Frame: at Day 0
|
CGH array
|
at Day 0
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Christophe Delacourt, MD, PhD, Necker-Enfants Malades Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Lezmi G, Vibhushan S, Bevilaqua C, Crapart N, Cagnard N, Khen-Dunlop N, Boyle-Freyssaut C, Hadchouel A, Delacourt C. Congenital cystic adenomatoid malformations of the lung: an epithelial transcriptomic approach. Respir Res. 2020 Feb 4;21(1):43. doi: 10.1186/s12931-020-1306-5.
- Kotecha S, Barbato A, Bush A, Claus F, Davenport M, Delacourt C, Deprest J, Eber E, Frenckner B, Greenough A, Nicholson AG, Anton-Pacheco JL, Midulla F. Antenatal and postnatal management of congenital cystic adenomatoid malformation. Paediatr Respir Rev. 2012 Sep;13(3):162-70; quiz 170-1. doi: 10.1016/j.prrv.2012.01.002. Epub 2012 Apr 25.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 11, 2012
Primary Completion (Actual)
October 11, 2015
Study Completion (Actual)
October 11, 2015
Study Registration Dates
First Submitted
November 19, 2012
First Submitted That Met QC Criteria
November 19, 2012
First Posted (Estimated)
November 22, 2012
Study Record Updates
Last Update Posted (Estimated)
September 8, 2025
Last Update Submitted That Met QC Criteria
September 1, 2025
Last Verified
September 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P100510
- 2012-A00538-35 (Registry Identifier: ID-RCB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Cystic Adenomatoid Malformation (CCAM)
-
University of California, San FranciscoChildren's Hospital of Philadelphia; Children's Hospital Medical Center, CincinnatiTerminatedCongenital Cystic Adenomatoid MalformationUnited States
-
Children's Hospital of PhiladelphiaCompletedCongenital Cystic Adenomatoid MalformationUnited States
-
Erasmus Medical CenterRecruitingCongenital Pulmonary Airway MalformationNetherlands
-
Lei XiaomingCompletedCystic Adenomatoid Malformation of Lung, Congenital | Bronchopulmonary Sequestration | Bronchogenic CystChina
-
Jiexiong FengRecruitingChildren | Thoracoscopic Surgery | Indocyanine Green | Congenital Pulmonary Airway Malformation | Pulmonary SequestrationChina
-
King's College Hospital NHS TrustKing's College LondonCompletedCongenital Disorders | Pulmonary Arteriovenous MalformationUnited Kingdom
-
Carmel Medical CenterUnknown
-
Delta University for Science and TechnologyCompletedIntralesional Injection of Cystic Hygroma | Cystic Hygroma (Macro-cystic Lymphatic Malformation)Egypt
-
Murdoch Childrens Research InstituteRoyal Children's Hospital; Peter MacCallum Cancer Centre, AustraliaRecruitingArteriovenous Malformations | Vascular Malformations | MAP2K1 Gene Mutation | PIK3CA-related Overgrowth Spectrum | Vascular Anomalies | Lymphangioma | Lymphatic Malformation | KRAS G12D | Venous Malformation | Vascular Anomaly | KRAS G12C | PI3K Gene Mutation | Slow-Flow Vascular Malformation | Fast-Flow Vascular... and other conditionsAustralia
-
Children's Hospital of Fudan UniversitySecond Affiliated Hospital of Wenzhou Medical University; Guangzhou Women and... and other collaboratorsRecruitingGenetic Disease | Congenital Malformation | Multiple MalformationChina
Clinical Trials on Patient
-
University Hospital FreiburgCompletedDepression | Acute Low Back PainGermany
-
Taipei Medical UniversityNational Science Council, TaiwanUnknownRadiographic Contrast Agent NephropathyTaiwan
-
University of Alabama at BirminghamPfizer Independent Grants for Learning and ChangeCompletedRheumatoid ArthritisUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); Northwestern MedicineCompleted
-
Centre for Evidence-Based Practice, BelgiumBelgian Red CrossCompleted
-
University of Colorado, DenverDenver Health and Hospital Authority; Rocky Mountain Human Services; El Grupo...Completed
-
Hospital of South West JutlandCompletedDiabetes Mellitus, Type 1 | Patient Reported Outcome | Health Care Economics and OrganizationsDenmark
-
ArdelyxAstraZenecaCompletedEnd Stage Renal Disease | ESRD | Chronic Kidney Disease Stage 5United States
-
University of WashingtonCompletedImplantable Cardioverter Defibrillator (ICD)United States
-
Denver Health and Hospital AuthorityUniversity of Colorado, DenverCompletedObesity | Overweight | ChildrenUnited States